Related references
Note: Only part of the references are listed.Determination of Rifampin Concentrations by Urine Colorimetry and Mobile Phone Readout for Personalized Dosing in Tuberculosis Treatment
Claire Szipszky et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2021)
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis
Jan-Willem C. Alffenaar et al.
CLINICAL INFECTIOUS DISEASES (2020)
Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin
Simone H. J. van den Elsen et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Challenging the management of drug-resistant tuberculosis
Hannah Yejin Kim et al.
LANCET (2020)
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid
Simone H. J. van den Elsen et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Therapeutic Drug Monitoring: The Need for Practical Guidance
Jan-Willem C. Alffenaar et al.
CLINICAL INFECTIOUS DISEASES (2019)
Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis
Samiksha Ghimire et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
Mohammad H. Al-Shaer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Payam Nahid et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
Sergey Borisov et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients
Samiksha Ghimire et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
Charles A. Peloquin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Lack of penetration of amikacin into saliva of tuberculosis patients
Simone H. J. van den Elsen et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment
Isaac Zentner et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2018)
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis
Devyani Deshpande et al.
CLINICAL INFECTIOUS DISEASES (2018)
Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients
Simone H. J. van den Elsen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians
Jan-Willem C. Alffenaar et al.
CLINICAL INFECTIOUS DISEASES (2017)
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Lina Davies Forsman et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Membrane Filtration Is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug Monitoring
Simone H. J. van den Elsen et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2017)
A Systematic Review Of Salivary Versus Blood Concentrations Of Anti-Tuberculosis Drugs And Their Potential For Salivary Therapeutic Drug Monitoring
Simone H.J. van den Elsen et al.
THERAPEUTIC DRUG MONITORING (2017)
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid et al.
CLINICAL INFECTIOUS DISEASES (2016)
End TB with precision treatment!
Evelien P. M. van der Burgt et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics
Samiksha Ghimire et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB
Samiksha Ghimire et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs
Anette Veringa et al.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY (2016)
Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis
J. Peter Cegielski et al.
CLINICAL INFECTIOUS DISEASES (2014)
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients
K. J. M. Aung et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2014)
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience
A. D. Pranger et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Diagnostics for the developing world
D Mabey et al.
NATURE REVIEWS MICROBIOLOGY (2004)
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
T Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Share Paper
